US-FED-00000382700 - TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs Platform - Deadline December 15,2026

The Bacterial Lipid Nanodiscs Platform developed by Los Alamos National Laboratory provides a new way to study entire bacterial membranes in a controlled, nanoscale format derived directly from native lipid extracts. Researchers gain access to membrane components that typically remain difficult to isolate, stabilize or analyze, enabling more accurate evaluation of immunogenic lipids and membraneassociated targets. The platform offers a safer alternative to handling live highrisk pathogens while preserving the biological context that drives meaningful insights for vaccine design and antimicrobial discovery such as therapeutic antibodies to conserved lipids on bacterial membranes.How it WorksThe Bacterial Lipid Nanodiscs Platform creates uniform nanoscale discs from total lipid extracts harvested from bacterial membranes. Membrane scaffold protein MSP1D1 encases the lipid mixture and forms a stable disc roughly 10 nanometers wide. The resulting particles retain the full complement of native bacterial lipids, arranged in a membranelike environment that supports realistic biological interactions without requiring synthetic lipids or live cells.Technical DescriptionThe method adapts established nanodisc assembly techniques to incorporate entire bacterial lipid extracts rather than defined synthetic lipid mixtures. Total lipids from a pathogen are solubilized, combined with MSP1D1 and dialyzed under controlled conditions to allow the scaffold protein to form a discoidal structure around the heterogeneous lipid population. The process yields nanoparticles that represent the membrane environment of the source organism, including amphiphilic molecules that typically resist purification or structural study when isolated from their native context.The approach was demonstrated using Yersinia pestis, chosen to illustrate how membrane characterization can proceed without the hazards associated with live Tier 1 pathogens. The method captures lipopolysaccharides (LPS) and diverse immunogenic lipids in an arrangement that mirrors their natural organization. Researchers can evaluate binding interactions, immunestimulating properties and potential antigenic targets in a stable platform that avoids the limitations of outer membrane vesicle purification. Furthermore, using this platform we have identified antibodies specific to E. coli LPS and Y. pestis membrane lipids. These antibodies are independently licensable.AdvantagesProvides membranelike structures using native bacterial lipidsAvoids the safety challenges of handling live pathogensOffers a broader and more realistic lipid environment than synthetic nanodiscsEnables improved assessment of membrane antigens and immune responsesSupports analysis of diverse bacterial species using a unified workflowCreates consistent nanoscale particles suitable for research and development settingsMarket ApplicationsLife Sciences Research (membrane biology, immunology)Vaccine Development (bacterial antigen discovery)Drug Discovery (membraneassociated targets)Diagnostics (lipid biomarker exploration)Biodefense Research (safe pathogen characterization)Development Status: TRL 3